Ona Therapeutics Appoints Dr. Antoine Yver to Lead Cancer Drug Development
- Dr. Antoine Yver appointed Chair of Ona Therapeutics' Board, bringing 35 years of oncology experience.
- His leadership is expected to advance Ona's ADCs, particularly ONA-255 for breast cancer and ONA-389 for colorectal cancer.
- Dr. Yver's expertise aligns with Ona's mission to innovate and enhance cancer therapies, focusing on patient-centric solutions.
Ona Therapeutics Strengthens Leadership with Appointment of Dr. Antoine Yver
Ona Therapeutics, a biotech firm focused on developing innovative antibody-drug conjugates (ADCs), announces the appointment of Dr. Antoine Yver as the Chair of its Board of Directors. Dr. Yver brings over 35 years of experience in oncology drug development, having played pivotal roles at leading pharmaceutical companies such as AstraZeneca and Daiichi Sankyo. He has been instrumental in the development and approval of 13 landmark cancer therapies, including notable drugs like ENHERTU®, TAGRISSO®, and LYNPARZA®. His extensive background positions him as a crucial asset as Ona Therapeutics transitions into a clinical-stage enterprise, particularly as it aims to advance its lead ADC, ONA-255, for breast cancer treatment, targeting clinical trials set to begin in early 2026.
The strategic appointment of Dr. Yver aligns seamlessly with Ona's mission to deliver transformative therapies in oncology. Valerie Vanhooren, Co-Founder and CEO of Ona Therapeutics, underscores the significance of Dr. Yver's expertise in rapidly advancing first-in-class oncology drugs, which will be vital for the company's growth trajectory. Dr. Yver's successful track record, especially in guiding ENHERTU from initial clinical trials to global approval, serves as a benchmark for the potential progress of Ona's pipeline. As the company prepares to navigate the clinical landscape, his leadership is expected to facilitate the advancement of not only ONA-255 but also the second ADC, ONA-389, aimed at addressing significant unmet medical needs in colorectal cancer and hepatocellular carcinoma.
With the oncology sector increasingly leaning towards personalized and innovative treatment options, Dr. Yver's patient-centric vision resonates with Ona's commitment to redefining cancer therapies. His role extends beyond mere oversight; it encompasses strategic guidance that is anticipated to bolster growth and enhance the overall value proposition of Ona Therapeutics during this critical phase of development. By harnessing his vast experience and industry insights, Ona is well-positioned to push the boundaries of ADC technology, aiming to make substantial contributions to cancer care.
In related industry developments, Mabwell, a biopharmaceutical company, has received Investigational New Drug (IND) clearance from the National Medical Products Administration in China for its CDH17-targeting ADC, 7MW4911. This ADC is designed to combat advanced solid tumors and demonstrates promising preclinical data, showing significant tumor regression in various cancers. Mabwell’s advancements highlight the growing focus on innovative ADCs within the oncology landscape, emphasizing the potential for new therapeutic options to address critical patient needs.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

